Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : qtrn(quintiles trans) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (55)	2/20/2000 5:54:00 PM
From: blackmerlin	Read Replies (1) \| Respond to of 105

Quintiles Trans. (QTRN) was listed with several other market gems as biotechnology, medical devives or diagnostics, or contract research organization (CRO) stocks under $30/share and worth looking into (see biobiznet.com). IMO, both CVD and QTRN look interesting and I am trying to decide what the upswing in biotech. stocks will mean for contract research organizations. I think it will probably mean more business for CRO-pharma, since even with big injections of capital, the biotech still need to build more infrastructure for producing compounds for conducting clinical trials or for manufacturing of approved compounds. Also new facilities would take substantial time in the qualification process and in getting online and geared up. Meanwhile a CRO with approved facilities could fill the gap. Any ideas? Jake Blackmerlin